Targeted platforms outperform universal mRNA delivery
The guest argued that the universal mRNA platform model is structurally flawed, requiring developers to instead build distinct, tissue-specific delivery platforms sequentially.
The argument
Using a SpaceX analogy, the guest asserted that companies like Moderna erred by assuming a single platform could address all organs. He argued that biotechs must first prove clinical viability with a single targeted application before expanding to more complex delivery mechanisms.
The thesis, stress-tested
✓ What validates it
- ✓Clinical data readouts for tissue-specific mRNA candidates
- ✓Moderna or other major mRNA players acquiring or developing tissue-specific delivery technologies
▸ Risks discussed
- ▸Developing multiple distinct platforms increases capital intensity
- ▸Regulatory bodies may require separate validation for each tissue-specific delivery mechanism
Hear it yourself
"But you will miss the early questions and the process of refining and refining and refining that ultimately led to those results. And to have one more note on that initial dinner where Jake and I met in Boston, there were two other attendees. You have Jamie, who is CEO of Alden Scientific, a l d e n, and then you have Phil, who is CEO of Holobiome, h o l o b I o m e. And both of them ended up winning ARPA h grants for the research and work that they're doing. And ARPA h, for people who don't know, is modeled on the defense agency DARPA, which is incredible in its own right."
03:30
AFFILIATE LINK · ZORTIX MAY EARN A COMMISSION · NEVER A RECOMMENDATION TO TRADE